“Korea is fully capable of developing new microbiome drugs"
By Nho, Byung Chul | translator Alice Kang
22.11.18 06:00:00
가나다라
0
“Success and failure in the development of medicines depend on identifying the keystone species in the human gut microbiome“
“Need to focus on developing treatments rather than simple Intestinal Microbiota to win in the global competition"
▲Eung-Bin Kim, Professor of Systems Biology at Yonsei University
“The development of metagenomics technology that extracts DNA directly from samples without culturing in 1998 enabled the field of human microbiome research to make a giant leap forward. The success and failure of innovative new microbiome-based therapeutics depend on identifying, standardizing, and materializing the keystone species in the human gut microbiome.“The development direction for new, innovative next-generation human microbiome-based therapeutics sought by Professor Eung-Bin Kim, Department of Systems Biology at Yonsei University, is focused on the understanding of the material cycle in the ecological structure.
More than 10,000 microorganisms inhabit our body (mouth, gut
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)